At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 9, 2026 at 08:00 ET
SpyGlass Pharma announced positive 12-month results from its Phase 1/2 trial of the BIM-IOL System, showing sustained intraocular pressure (IOP) reduction, high rates of freedom from topical glaucoma medications (97%), and vision outcomes comparable to standard IOLs. The data support the ongoing Phase 3 trials aimed at FDA approval via a 505(b)(2) NDA pathway.
- 97% of BIM-IOL patients discontinued all topical IOP-lowering therapy at 12 months
- 34% and 42% mean IOP reduction from baseline in 78-mcg and 39-mcg dose groups, respectively, vs. 35% in control
- 100% of patients achieved 20/32 or better vision, with mean BCDVA equivalent to 20/20
- Adverse event rates were similar across treatment and control groups, with no serious ocular events
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access